Revenue per share of Bitcoin Depot Inc. – NASDAQ:BTMWW

This article displays the revenue per share for Bitcoin Depot Inc. (NASDAQ: BTMWW). It shows historical values and changes over various periods, indicating its financial performance. The data is sourced from ICE Data Services and FactSet Research Systems.

Original reporting
Published Apr 1, 2026, 8:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 1, 2026, 8:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Revenue per share of Bitcoin Depot Inc. – NASDAQ:BTMWW — source image
Decision brief

The 30-second read

$BTMNeutralLow
01

Why it matters

The stable revenue per share suggests resilience but limited growth signals.

02

Market read

The data provides insight into the company's financial stability but has limited immediate trading implications.

03

What to watch

Possible upcoming catalysts not reflected in current data, such as new product launches or regulatory changes.

Relevance 6/10Timing: low

Background

Bitcoin Depot Inc. operates in the blockchain and cryptocurrency space, with revenue influenced by market volatility and adoption rates.

Company-level read

Ticker impact

$BTMNeutralMedium confidence
Context

The article provides historical revenue per share data for Bitcoin Depot Inc. (NASDAQ: BTMWW), indicating its financial performance over time.

Expected impact

Minimal short-term price movement expected; long-term impact uncertain.

Evidence & confidence

The data reflects historical performance without recent catalysts or significant deviations, leading to a neutral outlook.

Market effects

Limited sector impact due to the company's niche focus and stable revenue metrics.

Negligible impact on regional markets.

Low relevance to global market movements.

Counterpoint

Potential for undervaluation if revenue growth accelerates unexpectedly.

Key entities

  • Bitcoin Depot Inc.

    A company operating in the blockchain and cryptocurrency retail space.

  • ICE Data Services

    Source of historical financial data.

  • FactSet Research Systems

    Source of financial data and analytics.

Related articles

$RIVNMed

Rivian Just Earned a Buy Rating. Is Wall Street Seeing a Turning Point?

UBS upgraded Rivian (RIVN) to buy, citing a disconnect between its stock price and R2 EV opportunity. The analyst sees a buying opportunity ahead of expected production improvements and margin expansion. Rivian delivered 19,248 vehicles in Q3, with R2 as its best-selling model. However, the company reported an $80M automotive gross loss in Q3, offset by software and services profits. UBS kept its $17 price target unchanged.

$NVDAMed

Dan Niles: Nvidia’s Next CEO Will “Set a Low Bar” for Earnings

NVIDIA's CEO Jensen Huang resigned, with CFO Colette Kress becoming interim CEO. Analyst Dan Niles predicted this and warns of a potential low earnings bar. Analysts expect NVIDIA's EPS to triple by fiscal 2028, but the stock's valuation depends on these estimates holding. NVIDIA trades at about 14x forward earnings, near a three-year low. Kress will provide guidance on November 17.

$NVDALow

Here's what Colette Kress and Harvey Jones wrote to Nvidia employees

Nvidia's new interim CEO Colette Kress and board chair Harvey Jones sent emails to employees expressing gratitude and optimism following Jensen Huang's resignation. Kress praised employees' resilience and announced a company meeting for November 18. Jones highlighted Kress's role in Nvidia's growth and the board's confidence in her leadership.

$NVSMed

Novartis (NOT) Reports Sustained Remibrutinib Responses Through Week 52

Novartis reported Phase III RemIND trial results showing sustained efficacy of Rhapsido in chronic inducible urticaria through Week 52, with response rates of 46.8% to 83.3%. Patients switching from placebo to Rhapsido at Week 24 also showed similar responses. The drug was well-tolerated, with a safety profile consistent with prior studies. Novartis plans additional regulatory submissions based on these data.